TY - JOUR T1 - Imaging the Folate Receptor on Cancer Cells with <sup>99m</sup>Tc-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 701 LP - 704 DO - 10.2967/jnumed.113.133074 VL - 55 IS - 5 AU - Alan H. Maurer AU - Philip Elsinga AU - Stefano Fanti AU - Binh Nguyen AU - Wim J.G. Oyen AU - Wolfgang A. Weber Y1 - 2014/05/01 UR - http://jnm.snmjournals.org/content/55/5/701.abstract N2 - Folate receptor (FR) can be used as a therapeutic target because of its expression on different epithelial cancers, such as ovarian, non–small cell lung, endometrial, and breast cancer. Assessing FR expression in tumors may help to identify patients who can benefit from FR-targeted therapeutics, such as vintafolide and farletuzumab. Different methods exist to detect FR expression. Tissue sampling has limited clinical utility, mainly because it requires an invasive procedure. 99mTc-etarfolatide, a 99mTc-labeled folate conjugate, is in late-phase trials in Europe and the United States. It allows noninvasive, whole-body imaging of the FR. This review focuses on this FR-imaging agent and how it may be used to direct FR-targeted therapy. ER -